Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

with sunitinib or sorafenib. In the European Union (EU), Afinitor is approved for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

In the US, everolimus is available in different dosage strengths under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

With once-daily dosing, everolimus works by targeting mTOR in cancer cells, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism.

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in NET. Access to everolimus for NET has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for NET anywhere in the world.

Afinitor (everolimus) tablets important safety information

Afinitor is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives or to any of the excipients. Potentially serious adverse reactions to Afinitor include non-infectious pneumonitis and infections, for which patients should be monitored carefully and treated as needed. In addition, non-infectious pneumonitis may require temporary dose reduction and/or interruption or discontinuation. Patients with systemic invasive fungal infections should not receive Afinit
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014  Advanced Medical Isotope Corporation ... engaged primarily in the development of brachytherapy devices ... today announced that a Life Sciences Discovery Fund ... for which AMIC is the commercialization partner.  The ... for the proposal titled "Optimized Injectable Radiogels for ...
(Date:12/19/2014)... N.C. , Dec. 19, 2014 ... optimize a product,s web presence to reflect the ... websites, in particular, must meet the needs of ... and culture. According to recent ... than half of the participating companies averaged more ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Building a Best-in-Class Pharma Global Brand Website 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
(Date:12/22/2014)... Give a loved one the greatest gift ... and vitality. , For a limited time, HealthiPlus ( ... in special Holiday Wellness gift packages at drastically reduced ... bottle contains cutting-edge, proven nutritional support for joints, mental ... as we age. , Joint Health Plus ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... Xarelto Lawsuit News : Alonso ... has granted a request to centralize pending and subsequent ... Eastern District of Louisiana. The U.S. Judicial Panel On ... to transfer over 50 Xarelto cases–21 lawsuits and 30 ... court for consolidation under U.S. District Judge Eldon E. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 TheHardwareCity.com now ... glove with many useful features. Customers of the large ... have the new gloves delivered to their home or ... and hand tools that incorporate heavy duty magnets, which ... Glove allows workers to store metal parts on the ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... time could be counterproductive, researchers say , THURSDAY, Oct. 15 ... and essential part of building an immune response, and ... Tylenol -- after a shot could dampen that response, a ... that a child,s immune system is processing the immunization, providing ...
... Oct. 16 Mars Snackfood US announced today that Kyle Busch, ... Cup Series, plans to go pink this weekend during the NASCAR ... to support Susan G. Komen for the Cure®. Busch plans ... the wheel of an all pink M&M,S car during the Saturday ...
... , FORT WORTH, Texas, Oct. 16 Wound Management ... provider of specialty medical products, announced today that its subsidiary ... 24th Annual Clinical Symposium on Advances in Skin & ... opens on October 22 in San Antonio. , Dr. ...
... ... business, Dr. Philip Straka, a plastic surgeon in Houston , says he’s actually seeing ... ... be hitting a large number of economic sectors, but one area plastic surgeon says its ...
... ... of their "Tats for Tatas" fundraising campaign that will take place throughout ... company,s concerted efforts to raise awareness and funds for Breast Cancer Awareness, ... company will be donating 10% of all proceeds from sales throughout the ...
... to Feature Gena Rowlands , EAST BRUNSWICK, N.J., Oct. 15 ... return home to New Jersey to host a celebrity cocktail ... reception will raise money for National MS Society,s New Jersey ... New Jersey, where it is estimated that almost 10,000 people ...
Cached Medicine News:Health News:Tylenol May Weaken Effectiveness of Kids' Vaccines 2Health News:Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M&M's(R) And Dove(R) Chocolate Brands, as Well as Its Celebrated Race Team 2Health News:Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M&M's(R) And Dove(R) Chocolate Brands, as Well as Its Celebrated Race Team 3Health News:Wound Management Technologies Announces Clinical Study Presentation of CellerateRx(R) Technology at Leading Skin and Wound Care Conference 2Health News:Wound Management Technologies Announces Clinical Study Presentation of CellerateRx(R) Technology at Leading Skin and Wound Care Conference 3Health News:Houston Plastic Surgeon Seeing Growth in Aesthetic Enhancement Procedures Despite Rough Economy 2Health News:Houston Plastic Surgeon Seeing Growth in Aesthetic Enhancement Procedures Despite Rough Economy 3Health News:Atomic Tattoos Announces "Tats for Tatas" October Fundraising Event to Benefit Local Breast Cancer Research 2Health News:East Brunswick Native Returns Home to Help New Jersey Residents Living with MS 2
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
... is your system. CONMED's family of products ... New, state-of-the art generators feature proprietary Energy ... continuous synchronization of current and voltage in ... enables the system to sample current and ...
Medicine Products: